Dr. Pinder-Schenck is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
572 Marlin Ct
Redwood City, CA 94065Phone+1 267-251-1601
Education & Training
- University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2005 - 2008
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2007
- University of North Carolina HospitalsResidency, Internal Medicine, 2002 - 2005
- Stanford University School of MedicineClass of 2002
Certifications & Licensure
- CA State Medical License 2024 - 2026
- PA State Medical License 2016 - 2016
- FL State Medical License 2009 - 2015
Clinical Trials
Publications & Presentations
PubMed
- 31 citationsCDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibitionPriya K. Gopalan, Andres Gordillo Villegas, Chunxia Cao, Mary Pinder-Schenck, Alberto Chiappori
Oncotarget. 2018-12-21 - 24 citationsA phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma.Jhanelle E. Gray, Alberto Chiappori, Charles Williams, Tawee Tanvetyanon, Eric B. Haura
Cancer Immunology, Immunotherapy. 2018-09-12 - 51 citationsPhase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancerGiorgio V. Scagliotti, Jin Hyoung Kang, David J. Smith, Richard K. Rosenberg, Keunchil Park
Investigational New Drugs. 2016-06-27
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: